Edition:
United States

Denali Therapeutics Inc (DNLI.OQ)

DNLI.OQ on NASDAQ Stock Exchange Global Select Market

17.90USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$17.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
104,009
52-wk High
$25.50
52-wk Low
$14.80

Chart for

About

Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeuti... (more)

Overall

Beta: --
Market Cap(Mil.): $1,690.51
Shares Outstanding(Mil.): 94.44
Dividend: --
Yield (%): --

Financials

  DNLI.OQ Industry Sector
P/E (TTM): 16.50 240.92 34.18
EPS (TTM): 1.08 -- --
ROI: -- -5.87 13.17
ROE: -- -7.71 15.15

BRIEF-Denali Therapeutics Reports Q1 Loss Of $0.26 Per Share

* DENALI THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 11 2018

BRIEF-Denali Therapeutics Reports Qtrly Net Loss Per Share $0.74

* DENALI THERAPEUTICS ANNOUNCES FIRST-IN-HUMAN DOSING OF ITS RIPK1 INHIBITOR CLINICAL PROGRAM AND THE APPOINTMENT OF PETER KLEIN TO BOARD OF DIRECTORS; REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

Mar 19 2018

BRIEF-Temasek Holdings Dissolves Share Stake In Marin Software, Takes Share Stake In Denali Therapeutics

* TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN MARIN SOFTWARE INC - SEC FILING

Feb 14 2018

BRIEF-Denali Therapeutics, Lonza Pharma & Biotech Announce Exclusive Partnership To Develop And Produce Biologic Medicines

* DENALI THERAPEUTICS AND LONZA PHARMA & BIOTECH ANNOUNCE EXCLUSIVE PARTNERSHIP TO DEVELOP AND PRODUCE BIOLOGIC MEDICINES

Feb 08 2018

BRIEF-Takeda And Denali Therapeutics Collaborate To Develop Therapies For Neurodegenerative Diseases

* TAKEDA AND DENALI THERAPEUTICS COLLABORATE TO DEVELOP AND COMMERCIALIZE THERAPIES FOR NEURODEGENERATIVE DISEASES

Jan 05 2018

Earnings vs. Estimates